Literature DB >> 14764812

Genetic screening for melanocortin-4 receptor mutations in a cohort of Italian obese patients: description and functional characterization of a novel mutation.

Ferruccio Santini1, Margherita Maffei, Giovanni Ceccarini, Caterina Pelosini, Giovanna Scartabelli, Veronica Rosellini, Chiara Chiellini, Alessandro Marsili, Simonetta Lisi, Massimo Tonacchera, Patrizia Agretti, Luca Chiovato, Claudia Mammoli, Paolo Vitti, Aldo Pinchera.   

Abstract

Mutations in the human melanocortin-4 receptor (MC4-R) gene may account for up to 5.8% of morbid nonsyndromic obesity. We have screened 120 unrelated obese patients for variants of the MC4-R gene. Four heterozygous missense variants were detected, including two polymorphisms (Val(103)Ile and Ile(251)Leu) previously described in the literature. A novel heterozygous mutation (Glu(308)Lys) was detected in a 36-yr-old female patient. Compared with the wild-type receptor, cells expressing the mutated receptor showed a reduced stimulation of cAMP production and a reduction of radioactive alpha MSH binding. No segregation of the mutation with the obese phenotype could be demonstrated. A second, potentially pathogenic mutation (Ser(30)Phe) was detected in a 31-yr-old female patient. Functional analysis of the mutated receptor showed no change in the affinity to the natural ligand alpha MSH nor limited ability to stimulate cAMP production. Sixty lean subjects were also screened, and no additional variants of the MC4-R gene were observed, except for two individuals with the Val(103)Ile polymorphism. In conclusion, we have screened a population of Italian obese subjects for MC4-R variants, demonstrating a 1.7% prevalence of potentially pathogenic mutations. A novel heterozygous missense mutation (Glu(308)Lys) that impairs MC4-R functional activity in vitro was characterized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764812     DOI: 10.1210/jc.2003-031175

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  The MC4 receptor and control of appetite.

Authors:  R A H Adan; B Tiesjema; J J G Hillebrand; S E la Fleur; M J H Kas; M de Krom
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

2.  Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.

Authors:  Zhimin Xiang; Bettina Proneth; Marvin L Dirain; Sally A Litherland; Carrie Haskell-Luevano
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

3.  The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

Authors:  Ya-Xiong Tao
Journal:  Endocr Rev       Date:  2010-02-26       Impact factor: 19.871

4.  Binding of thyroglobulin (Tg) to the low-density lipoprotein receptor-associated protein (RAP) during the biosynthetic pathway prevents premature Tg interactions with sortilin.

Authors:  R Botta; S Lisi; G Rotondo Dottore; P Vitti; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-04-05       Impact factor: 4.256

5.  Increased constraints on MC4R during primate and human evolution.

Authors:  David A Hughes; Anke Hinney; Harald Brumm; Anne-Kathrin Wermter; Heike Biebermann; Johannes Hebebrand; Mark Stoneking
Journal:  Hum Genet       Date:  2008-11-15       Impact factor: 4.132

6.  The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29 563 individuals.

Authors:  E H Young; N J Wareham; S Farooqi; A Hinney; J Hebebrand; A Scherag; S O'rahilly; I Barroso; M S Sandhu
Journal:  Int J Obes (Lond)       Date:  2007-03-13       Impact factor: 5.095

7.  Prevalence of pathogenetic MC4R mutations in Italian children with early onset obesity, tall stature and familial history of obesity.

Authors:  Nicola Santoro; Grazia Cirillo; Zhimin Xiang; Rita Tanas; Nella Greggio; Giuseppe Morino; Lorenzo Iughetti; Alessandra Vottero; Alessandro Salvatoni; Mario Di Pietro; Antonio Balsamo; Antonino Crinò; Anna Grandone; Carrie Haskell-Luevano; Laura Perrone; Emanuele Miraglia del Giudice
Journal:  BMC Med Genet       Date:  2009-03-12       Impact factor: 2.103

8.  Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function.

Authors:  Wilfried Pott; Ozgür Albayrak; Anke Hinney; Johannes Hebebrand; Ursula Pauli-Pott
Journal:  Obes Facts       Date:  2013-03-06       Impact factor: 3.942

9.  Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations.

Authors:  Cæcilie Trier; Mette Hollensted; Theresia M Schnurr; Morten Asp Vonsild Lund; Tenna Ruest Haarmark Nielsen; Gao Rui; Ehm Astrid Andersson; Mathilde Svendstrup; Dorthe Sadowa Bille; Anette P Gjesing; Cilius Esmann Fonvig; Christine Frithioff-Bøjsøe; Marie Balslev-Harder; Shi Quan; Michael Gamborg; Oluf Pedersen; Lars Ängquist; Jens-Christian Holm; Torben Hansen
Journal:  Int J Obes (Lond)       Date:  2020-09-13       Impact factor: 5.095

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.